SPOTLIGHT: FDA fast tracks Shigamabs

Caprion Pharmaceuticals says the FDA has granted fast track status to Shigamabs to prevent infection with shigatoxin-producing bacteria. Caprion plans to launch a pivotal Phase II/III trial in early 2007. Report

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.